3
Announcements
Trials
Browse
Landscape
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Observational
1
Sponsor
Cancer Type
Dermatologic
1
Conditions
Skin Neoplasms
1
Multiple Sclerosis, Relapsing-Remitting
1
Multiple Sclerosis
1
Melanoma
1
Carcinoma, Basal Cell
1
Interventions
Blood Specimen Collection
14
Nivolumab
13
Ipilimumab
12
pembrolizumab
11
trametinib
9
Surveys and Questionnaires
9
Gene Expression Profiling
9
dabrafenib
8
Biopsy
6
Specimen Handling
5
Immunotherapy
5
Immunohistochemistry
5
Amplified Fragment Length Polymorphism Analysis
4
encorafenib
3
binimetinib
3
atezolizumab
3
Restraint, Physical
3
Quality of Life
3
Polymerase Chain Reaction
3
Introns
3
Flow Cytometry
3
Drug Therapy
3
Data Collection
3
tremelimumab
2
pimonidazole
2
cobimetinib
2
aldesleukin
2
Watchful Waiting
2
Vemurafenib
2
Therapeutics
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Observational
×
Melanoma
×
Natalizumab
×
Clear all
NCT06705608
2024-11-26
MS; FTY720
University of British Columbia
Completed
4,000 enrolled